Consultation on proposed commitments in respect of Vifor Pharma鈥檚 supply of intravenous iron
Consultation description
The Competition and Markets Authority (CMA) invites views on commitments offered by Vifor Pharma, in relation to our investigation into its conduct in the market for the supply of high-dose intravenous iron, under the Chapter II prohibition of the Competition Act 1998.
Our investigation relates to concerns that Vifor Pharma made potentially misleading claims about a competitor鈥檚 intravenous iron treatment, Monofer (supplied by Pharmacosmos), as compared to Vifor Pharma鈥檚 own product, Ferinject.
We provisionally consider that the proposed commitments address the competition concerns we identified, for the reasons set out in the Notice of Intention to Accept Commitments. Therefore, subject to consultation responses, we propose to accept the proposed commitments.
To comment on the commitments, email your response to聽[email protected]聽with the subject line 鈥楥ase 51377 鈥� Response to Vifor Proposed Commitments鈥�.
More information can be found on the聽investigation into Vifor Pharma聽case page.